PRTC
HealthcarePureTech Health plc
$16.64
+$0.00 (+0.00%)
Jan 5, 2026
Price History (1Y)
Analysis
PureTech Health plc is a biotechnology company listed on the market with a sector and industry classification of healthcare and biotechnology, respectively. The company has a market capitalization of $404.10M, revenue of $6.39M, and employs 56 individuals. From a financial health perspective, PureTech Health plc's profitability metrics are negative, with gross margin at 0.0%, operating margin at -2589.5%, and profit margin at 793.0%. The company also reports significant losses in EBITDA ($-115,718,000) and free cash flow ($-160,187,872). However, the return on equity is 9.4% and the debt-to-equity ratio is 44.33, indicating some level of leverage. Additionally, the company has $331.28M in cash and $163.57M in debt. In terms of valuation, PureTech Health plc's forward P/E ratio is -33.44, which suggests a significant discount to its peers. The revenue growth rate is 542.7% year-over-year, but earnings growth is not available due to the negative net income. The company does not pay dividends, with a payout ratio of 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About PureTech Health plc
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development; oral therapies based on defined bacterial consortia that is in phase 3 clinical stage; and engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers. Further, it develops voice-based technology platform that detects changes in the sound of voice that are linked with health conditions, including depression, anxiety, and respiratory disease. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $404.10M
- P/E Ratio
- 9.84
- 52-Week High
- $20.00
- 52-Week Low
- $13.30
- Avg Volume
- 2.44K
- Beta
- 0.70
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 56